Agios Pharmaceuticals (NASDAQ:AGIO) Stock Rating Upgraded by StockNews.com

StockNews.com upgraded shares of Agios Pharmaceuticals (NASDAQ:AGIO) from a sell rating to a hold rating in a research report report published on Wednesday.

Other analysts also recently issued reports about the company. Cantor Fitzgerald restated an “overweight” rating on shares of Agios Pharmaceuticals in a research report on Friday, September 20th. Scotiabank began coverage on shares of Agios Pharmaceuticals in a report on Wednesday. They set a “sector outperform” rating and a $51.00 price target for the company. Leerink Partnrs lowered shares of Agios Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Friday, September 27th. Leerink Partners cut shares of Agios Pharmaceuticals from an “outperform” rating to a “market perform” rating and cut their target price for the stock from $60.00 to $56.00 in a report on Friday, September 27th. Finally, Raymond James reissued an “outperform” rating and set a $51.00 price target on shares of Agios Pharmaceuticals in a report on Thursday, October 10th. Five investment analysts have rated the stock with a hold rating and four have given a buy rating to the stock. According to MarketBeat, Agios Pharmaceuticals presently has an average rating of “Hold” and a consensus price target of $52.00.

Agios Pharmaceuticals Stock Up 3.1 %

Shares of NASDAQ AGIO opened at $45.50 on Wednesday. Agios Pharmaceuticals has a 52-week low of $19.80 and a 52-week high of $53.28. The business has a 50-day moving average price of $44.62 and a 200 day moving average price of $41.08. The stock has a market cap of $2.58 billion, a PE ratio of -7.20 and a beta of 0.75.

Agios Pharmaceuticals (NASDAQ:AGIO) last posted its quarterly earnings data on Thursday, August 1st. The biopharmaceutical company reported ($1.69) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.60) by ($0.09). The firm had revenue of $8.60 million during the quarter, compared to analysts’ expectations of $9.34 million. Agios Pharmaceuticals had a negative net margin of 1,165.69% and a negative return on equity of 47.05%. The business’s quarterly revenue was up 28.4% on a year-over-year basis. During the same quarter last year, the business earned ($1.51) earnings per share. Sell-side analysts anticipate that Agios Pharmaceuticals will post -4.87 earnings per share for the current year.

Insider Buying and Selling

In other Agios Pharmaceuticals news, CFO Cecilia Jones sold 2,542 shares of the firm’s stock in a transaction dated Thursday, September 26th. The stock was sold at an average price of $49.03, for a total transaction of $124,634.26. Following the transaction, the chief financial officer now directly owns 20,158 shares in the company, valued at $988,346.74. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. In related news, CFO Cecilia Jones sold 2,542 shares of the firm’s stock in a transaction that occurred on Thursday, September 26th. The stock was sold at an average price of $49.03, for a total value of $124,634.26. Following the transaction, the chief financial officer now directly owns 20,158 shares of the company’s stock, valued at approximately $988,346.74. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Brian Goff sold 11,091 shares of the business’s stock in a transaction that occurred on Thursday, August 8th. The stock was sold at an average price of $42.75, for a total value of $474,140.25. Following the completion of the sale, the chief executive officer now owns 78,792 shares of the company’s stock, valued at approximately $3,368,358. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 4.93% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the company. Acadian Asset Management LLC bought a new stake in Agios Pharmaceuticals during the second quarter valued at about $37,000. Quest Partners LLC acquired a new position in shares of Agios Pharmaceuticals during the 2nd quarter worth about $40,000. CWM LLC boosted its stake in Agios Pharmaceuticals by 554.7% during the 3rd quarter. CWM LLC now owns 2,167 shares of the biopharmaceutical company’s stock valued at $96,000 after purchasing an additional 1,836 shares during the period. North Star Asset Management Inc. acquired a new stake in Agios Pharmaceuticals in the 2nd quarter valued at approximately $216,000. Finally, XTX Topco Ltd bought a new position in Agios Pharmaceuticals in the 2nd quarter worth approximately $230,000.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.